

273th Business Plan Presentations Held on December 9 2025

Tech Hub Yokohama

1. TL Genomics Inc. President Mr. Tomohiro Kubo Established in January 2015 Capital stock : USD \$ 1,000,000

TL Genomics Inc. is engaged in business in the following two fields.

1) Fertility testing: The company carries out healthcare examinations that measure the degree of aging and make the potential for pregnancy visible. Through medical institutions, it makes sales to women in the phase of preconception and that of infertility consultation.

2) Chimerism testing for recurrence of diseases and conditions after bone marrow transplantation: The company is promoting the development of in vitro diagnostics and diagnostic and therapeutic pharmaceuticals covered by the national health insurance program. It is planning to market these products in 2028.

【Re-Cap】 *Ninshinyoku*, a Japanese term for fertility, was originally coined by TL Genomics, and is aimed at having a social impact. Fertility tests take samples of blood from the woman and measure the phenomenon whereby the two X chromosomes disappear from the body along with aging. As compared to those of other companies, TL Genomics testing related to aging is superior in the following three respects: 1) it has a high reproducibility regardless of the patient's physical condition, 2) it has standard values, and 3) it yields evidence related to pregnancy. Surprisingly, there are no products for testing ease of conception, and the market for fertility testing is estimated at about 25.5 billion yen.

Bone marrow transplants are a niche market whose demand is estimated at about 4,000 persons. Chimerism testing is performed to determine whether or not the blood cells of the donor are being engrafted in the body of the patient. Even after the passage of many years, the diseases or conditions targeted by marrow transplant may recur. Patients therefore undergo periodic testing. The company is developing products with a detection sensitivity that is a remarkable ten times as high as the conventional products and will be eligible for coverage by the national health insurance program. Mr. Kubo said that, in the future, he wants patients to be able to easily do tests at their homes anytime.



2. Logon System Co.,Ltd. President Mr. Iizuka Akio Established in May 1996 Capital stock : USD \$ 150,000

Logon System Co., Ltd.'s business is centered on development of web systems using mainly Java and Hypertext Preprocessor(PHP). It has special competence in the development of screen programs and server-side programs adapted to different types of devices, i.e., personal computers, tablets, and iPhones.

In recent years, the company has been putting effort into development making extensive use of AI technology. A particular focus is the development of AI-related products, such as systems for compliance with the Electronic Book Maintenance Act using AI optical character recognition (AI-OCR) and business support applications incorporating generative AI. The development process consists of the sequence of requirement definition, basic design, detailed design, manufacture, and testing. The company consequently has a one-stop capability for executing consigned development.

【Re-Cap】 The Electronic Book Maintenance Act was enacted on January 1, 2024. It obligates the preparation of an index ledger enabling the requisite information to be found immediately in storage of electronic transactional data. It may be likened to the index of a book. Logon System's products were created with the idea of making the related work at small and medium enterprises more efficient. To this end, they have the following four features: 1) a cloud format allowing use anywhere, 2) automatic processing in units of folders, 3) unlimited scope of application, and 4) secure design in compliance with pertinent laws and regulations. At present, the major functions have basically been completed; the sole remaining task is the final check before release. The company is aiming for commercialization and sales launch next summer. The AI-OCR market is rapidly expanding, and is forecast to amount to about 100 billion yen in 2029 in Japan alone.



3. AMI Inc. President Mr. Shinpei Ogawa

Presenter Mr. Ginga Sato, Director, Executive Vice President, Business Development Division

Established in November 2015 Capital stock : USD \$ 5,360,000

AMI is a start-up firm whose mission is to achieve a society providing the optimal medical care to anyone, anytime and anywhere. It Offers Cardio EGG (the former AMI-SSS01 Series Phonocardiograph), which is a medical device that can record and analyze Cardiac sounds and electrocardiograms and has been approved under the Pharmaceutical Affairs Act, and Cloud Choshin®, a system to support remote medical services. It has redefined a system with the four components of Cardio-EGG, Cloud Choshin®, AI technology, and evidence as its "Super Stethoscope." It is hoping to connect lives that can be saved to medical treatment by making it possible for even unspecialized physicians to perform examinations within a short time.

【Future developments】 Going forward, besides selling equipment and instating a usage-based billing scheme for AI analysis, AMI wants to broaden its business and become a platformer for hospital-clinic cooperation linking non-specialized and specialized physicians with the system cloud. Its aspirations also include entry into the domain of monitoring diagnoses and new pharmaceutical development in Japan, and promotion of a globalized development by acquiring FDA approval in the United States and preparing redemption reserves.

【Re-Cap】 Mr. Sato said that he is often asked about the difference between the "super stethoscope" and electrocardiogram testing. He replies that, to begin with, whereas electrocardiography is performed to discover conditions such as arrhythmia and acute myocardial infarction based on information that can be acquired from electrocardiogram testing (i.e., the electrical activity of the heart and cardiac muscle), AMI's device can discover conditions such as congestive heart failure and valvular heart disease with information that can be acquired from cardiac sounds. According to him, the solutions provided by his company can even lead to the birth of "new value" in Japan and the rest of the world, through the following benefits: 1) improvement of the quality of medical services, 2) reform of work styles, and 3) contribution to management.



【Message from Vice Chairman Masatoshi Go】 We have been holding these business presentation meetings since 2000, and this year therefore marked their 25th anniversary. Around the time when the meetings began, desires to promote venture firms were gathering momentum among both public administrative authorities and private enterprises. The companies appearing behind the podium at this forum are each given 30 minutes to make their presentations. Today, this length has also become a point of differentiation from other forums for corporate pitches. The meetings rest on the referrals to presenting companies from people acquainted with them, and this is also the reason why they have been able to continue so long. We are planning to begin a partnership with the Technology Advanced Metropolitan Area (TAMA) Association starting next year, and I hope to expand our network more and more. In 2026 as well, we are determined to make the meeting an occasion offering introductions to interesting companies, and are counting on your continued support to this end.

